Clinical trials: Proliferative Diabetic Retinopathy
Diabetic Retinopathy
Ozurdex in Reducing PVR After Vitreotomy in PDR
Diabetic retinopathy is a significant source of visual morbidity in the adult population. Complications of diabetic retinopathy include ischemic maculopathy, macular edema, and sequelae of fibrovascular proliferation, such as…
- Trial name
- NCT05415826
- Testing
- slow-release dexamethasone implant
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Proliferative Diabetic Retinopathy
Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).Although pars plana vitrectomy (PPV) is the cornerstone for treatment of advanced PDR, related…
- Trial name
- NCT05414149
- Testing
- preoperative intravitreal injections of ranibizumab or conbercept
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University People's Hospital
Proliferative Diabetic Retinopathy
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).Intravitreal injection of anti-VEGF drugs is a good adjunct to vitreous surgery for severe PDR.
- Trial name
- NCT05408416
- Testing
- preoperative group and intraoperative group
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Peking University People's Hospital
Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic
Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy
Diabetic retinopathy has been found progress in 20-70% diabetic patient after cataract phacoemulsification surgery. Intravitreal injection of anti-VEGF Ranibizumab is an important treatment for diabetic retinopathy including…
- Conditions
- Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy
- Trial name
- NCT05386160
- Testing
- Ranibizumab Injection [Lucentis], Phacoemulsification
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Ruijin Hospital
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
Given the high number of people with DMO and PDR, the need for patients to be seen at short follow-up intervals, the need for frequent treatments and the requirement for long-term follow-up, there is a very large workload in…
- Trial name
- EMERALD (NCT03490318)
- Where
- 13 sites in United Kingdom
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Belfast Health and Social Care Trust
Neovascular Age-related Macular Edema, Diabetic Macular Edema
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of…
- Conditions
- Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05222633
- Testing
- Ranibizumab, Aflibercept, Conbercept
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wenbin Wei
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema
Ultra-wide field fluorescein angiography can detect the response of anti VGEF therapy such as Avastin on retinal ischemia in the setting of diabetic macular edema.
- Conditions
- Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT02096874
- Testing
- Bevacizumab
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- King Khaled Eye Specialist Hospital
Proliferative Diabetic Retinopathy
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial growth factor (anti-VEGF) therapy with…
- Trial name
- Protocol S (NCT01489189)
- Testing
- Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
- Where
- 48 sites in United States
- Volunteers
- 305 people
- Sponsor
- Jaeb Center for Health Research
Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal capillary non-perfusion (RNP) associated…
- Trial name
- RECOVERY (NCT02863354)
- Testing
- Aflibercept
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Charles C Wykoff, PhD, MD
Proliferative Diabetic Retinopathy
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.
- Trial name
- NCT02753400
- Testing
- emixustat hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Kubota Vision Inc.
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Although vitreous hemorrhage (VH) from proliferative diabetic retinopathy (PDR) can cause acute and dramatic vision loss for patients with diabetes, there is no current, evidence-based clinical guidance as to what treatment…
- Trial name
- AB (NCT02858076)
- Testing
- 2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
- Where
- 62 sites in United States, Canada
- Volunteers
- 205 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
- Conditions
- Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- NCT01571232
- Testing
- dexamethasone intravitreal implant, intravitreal bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Retina Macula Institute
Proliferative Diabetic Retinopathy
Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR
In this randomized 3-armed clinical trial, 105 eyes with PDR will be included and divided randomly into 3 groups: IVB group (35 eyes) that receive 4 monthly IVB injections and then rescue IVB, PRP group (35 eyes) that undergo…
- Trial name
- NCT04800679
- Testing
- receive 4 monthly IVB injections and then rescue IVB, PRP group, IVB injections and a modified laser
- Where
- Iran
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Proliferative Diabetic Retinopathy
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
Panretinal photocoagulation (PRP) has been the standard treatment for Proliferative diabetic retinopathy (PDR) since the Diabetic Retinopathy Study demonstrated its benefit nearly 40 years ago,but PRP has inevitable adverse…
- Trial name
- NCT02911311
- Testing
- intravitreal injection of conbercept, PRP
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Sun Yat-sen University
Diabetic Retinopathy, Proliferative Vitreoretinopathy
Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics
The surgically-harvested eye tissue (ie. vitreous-retinal proliferative membrane, outflow pathway, retinas, and pterygium) is a complex tissue responsible for maintaining intraocular homeostasis or mediating ocular pathogenesis.
- Conditions
- Diabetic Retinopathy, Proliferative Vitreoretinopathy, Pterygium, Glaucoma
- Trial name
- Eyesinglecell (NCT04682054)
- Testing
- ocular surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diabetic Macular Edema, Sleep Apnea
Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study
The purpose of this study is to evaluate the relationship between DME and obstructive sleep apnea (OSA). OSA impacts millions of North Americans, many of whom are undiagnosed.
- Conditions
- Diabetic Macular Edema, Sleep Apnea, Non Proliferative Diabetic Retinopathy
- Trial name
- DME-OSA (NCT03597815)
- Testing
- Aflibercept 40 MG/ML [Eylea], OSA diagnostic test - overnight sleep study, CPAP therapy for OSA positive patients
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Uptown Eye Specialists
Non-proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that receive 6 bimonthly intravitreal…
- Trial name
- NCT04511715
- Testing
- Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression
- Volunteers
- 100 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
To investigate ranibizumab's benefit on prevention of early postoperative vitreous haemorrhage in PDR-DME patients receiving vitrectomy.
- Trial name
- NCT04464694
- Testing
- Ranibizumab, Pars plana vitrectomy
- Where
- 3 sites in China
- Volunteers
- 142 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Severe Non-proliferative Diabetic Retinopathy
Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy
Diabetic retinopathy (DR) is a leading cause of new cases of blindness in people aged 20 to 65 years worldwide. Patients with DR may go on to develop a more severe form of the disease called Proliferative Diabetic Retinopathy…
- Trial name
- PRPhS (NCT02309502)
- Testing
- Green Pascal, Yellow Pascal
- Where
- United Kingdom
- Sponsor
- Manchester University NHS Foundation Trust
Naive Patients With Uncomplicated Proliferative Diabetic Retinopathy
Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.
Proliferative diabetic retinopathy is a serious complication of diabetes mellitus, partly consecutive to upregulation of vascular endothelial growth factor (VEGF) as a consequence of retinal ischemia leads.
- Trial name
- NCT02151695
- Testing
- panretinal photocoagulation, Aflibercept intravitreal injections
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Poitiers University Hospital